TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), today announced the publication of the final decision memorandum regarding Medicare coverage of Microvolt T-Wave Alternans (MTWA) diagnostic testing. The Centers for Medicare & Medicaid Services (CMS) reaffirmed coverage of MTWA using the spectral analysis method and found insufficient evidence for coverage of MTWA using any other method.
